Rosacea - Pipeline Review, H1 2020
Rosacea - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rosacea - Pipeline Review, H1 2020, provides an overview of the Rosacea (Dermatology) pipeline landscape.
Rosacea is a chronic and potentially life-disruptive disorder primarily of the facial skin, often characterized by flare-ups and remissions. Symptoms include frequent redness of the face, or flushing, small, red lines under the skin, a swollen nose and thick skin, usually on the forehead, chin, and cheeks. The predisposing factors include age and family history of rosacea. Treatment includes antibiotics and acne drugs.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rosacea - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Rosacea (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Rosacea (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Rosacea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 10, 5 and 7 respectively.
Rosacea (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rosacea - Pipeline Review, H1 2020, provides an overview of the Rosacea (Dermatology) pipeline landscape.
Rosacea is a chronic and potentially life-disruptive disorder primarily of the facial skin, often characterized by flare-ups and remissions. Symptoms include frequent redness of the face, or flushing, small, red lines under the skin, a swollen nose and thick skin, usually on the forehead, chin, and cheeks. The predisposing factors include age and family history of rosacea. Treatment includes antibiotics and acne drugs.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rosacea - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Rosacea (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Rosacea (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Rosacea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 10, 5 and 7 respectively.
Rosacea (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Rosacea (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Rosacea (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rosacea (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rosacea (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rosacea (Dermatology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rosacea (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rosacea (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Rosacea - Overview
Rosacea - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Rosacea - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Rosacea - Companies Involved in Therapeutics Development
Accuitis Pharmaceuticals Inc
Afecta Pharmaceuticals Inc
Aiviva BioPharma Inc
AlfaSigma SpA
AOBiome LLC
Biomimetix JV LLC
BioPharmX Inc
Botanix Pharmaceuticals Ltd
Cellix Bio Pvt Ltd
Cutanea Life Sciences Inc
Dermata Therapeutics LLC
ELORAC Inc
Emeriti Pharma AB
GlycoMira Therapeutics Inc
Hovione FarmaCiencia SA
Maruho Co Ltd
Matrisys Bioscience Inc
Menlo Therapeutics Inc
Sol-Gel Technologies Ltd
Sunny Pharmtech Inc
Tarsus Pharmaceuticals Inc
TWi Biotechnology Inc
Rosacea - Drug Profiles
AC-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACUD-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AFX-4031 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AIV-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
B-244 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
benzoyl peroxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMX-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPX-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BTX-1702 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
carbamide peroxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLX-1621 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLXDER-621 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLXDER-622 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLXDER-623 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DMT-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
doxycycline hyclate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EP-0003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FMX-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-0111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HY-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-1220 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MSB-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omiganan pentahydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
phenylbutyrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rifaximin DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rosacea - Dormant Projects
Rosacea - Discontinued Products
Rosacea - Product Development Milestones
Featured News & Press Releases
Feb 18, 2020: Foamix announces integrated efficacy results from the FMX103 1.5% Topical Minocycline Foam Phase 3 program for Rosacea
Feb 13, 2020: Sol-Gel announces positive topline results from open-label, long-term safety study of Epsolay for treatment up to 52 Weeks
Feb 06, 2020: Foamix announces publication of Phase 3 Studies evaluating FMX103 for the treatment of papulopustular rosacea in Journal of the American Academy of Dermatology
Jan 21, 2020: Sol-Gel announces presentation Epsolay at the 16th Annual Maui Derm for Dermatologists 2020 Meeting
Dec 09, 2019: Botanix initiates BTX 1702 rosacea study
Oct 23, 2019: Foamix enters into manufacturing and supply agreement For FMX103
Oct 17, 2019: Foamix announces FDA acceptance of its New Drug Application for FMX103 Minocycline foam for the treatment of Moderate-to-Severe Papulopustular Rosacea
Oct 16, 2019: Sol-Gel to present on potential of Sol-Gel Microencapsulation Technology in Rosacea at 39th Annual Fall Clinical Dermatology Conference
Oct 10, 2019: Foamix to present data on FMX-103 at 39th Annual Fall Clinical Dermatology Conference
Sep 20, 2019: Hovione announces successful end-of-phase 2 meeting with the FDA and outlines phase 3 program for minocycline topical gel
Aug 06, 2019: Foamix seeks FDA approval for FMX103 to treat rosacea
Jul 08, 2019: Sol-Gel announces positive top-line results from epsolay phase 3 program in papulopustular Rosacea
Jun 26, 2019: BioPharmX reports positive results from BPX-041 trial for rosacea
May 22, 2019: BioPharmX announces last patient visit in Phase 2b trial of BPX-04 for papulopustular rosacea
Mar 04, 2019: BioPharmX completes enrollment in phase 2b trial of BPX-04 for patients with papulopustular rosacea
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Rosacea - Overview
Rosacea - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Rosacea - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Rosacea - Companies Involved in Therapeutics Development
Accuitis Pharmaceuticals Inc
Afecta Pharmaceuticals Inc
Aiviva BioPharma Inc
AlfaSigma SpA
AOBiome LLC
Biomimetix JV LLC
BioPharmX Inc
Botanix Pharmaceuticals Ltd
Cellix Bio Pvt Ltd
Cutanea Life Sciences Inc
Dermata Therapeutics LLC
ELORAC Inc
Emeriti Pharma AB
GlycoMira Therapeutics Inc
Hovione FarmaCiencia SA
Maruho Co Ltd
Matrisys Bioscience Inc
Menlo Therapeutics Inc
Sol-Gel Technologies Ltd
Sunny Pharmtech Inc
Tarsus Pharmaceuticals Inc
TWi Biotechnology Inc
Rosacea - Drug Profiles
AC-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACUD-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AFX-4031 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AIV-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
B-244 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
benzoyl peroxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMX-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPX-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BTX-1702 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
carbamide peroxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLX-1621 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLXDER-621 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLXDER-622 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLXDER-623 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DMT-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
doxycycline hyclate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EP-0003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FMX-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-0111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HY-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-1220 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MSB-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omiganan pentahydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
phenylbutyrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rifaximin DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rosacea - Dormant Projects
Rosacea - Discontinued Products
Rosacea - Product Development Milestones
Featured News & Press Releases
Feb 18, 2020: Foamix announces integrated efficacy results from the FMX103 1.5% Topical Minocycline Foam Phase 3 program for Rosacea
Feb 13, 2020: Sol-Gel announces positive topline results from open-label, long-term safety study of Epsolay for treatment up to 52 Weeks
Feb 06, 2020: Foamix announces publication of Phase 3 Studies evaluating FMX103 for the treatment of papulopustular rosacea in Journal of the American Academy of Dermatology
Jan 21, 2020: Sol-Gel announces presentation Epsolay at the 16th Annual Maui Derm for Dermatologists 2020 Meeting
Dec 09, 2019: Botanix initiates BTX 1702 rosacea study
Oct 23, 2019: Foamix enters into manufacturing and supply agreement For FMX103
Oct 17, 2019: Foamix announces FDA acceptance of its New Drug Application for FMX103 Minocycline foam for the treatment of Moderate-to-Severe Papulopustular Rosacea
Oct 16, 2019: Sol-Gel to present on potential of Sol-Gel Microencapsulation Technology in Rosacea at 39th Annual Fall Clinical Dermatology Conference
Oct 10, 2019: Foamix to present data on FMX-103 at 39th Annual Fall Clinical Dermatology Conference
Sep 20, 2019: Hovione announces successful end-of-phase 2 meeting with the FDA and outlines phase 3 program for minocycline topical gel
Aug 06, 2019: Foamix seeks FDA approval for FMX103 to treat rosacea
Jul 08, 2019: Sol-Gel announces positive top-line results from epsolay phase 3 program in papulopustular Rosacea
Jun 26, 2019: BioPharmX reports positive results from BPX-041 trial for rosacea
May 22, 2019: BioPharmX announces last patient visit in Phase 2b trial of BPX-04 for papulopustular rosacea
Mar 04, 2019: BioPharmX completes enrollment in phase 2b trial of BPX-04 for patients with papulopustular rosacea
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Rosacea, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Rosacea - Pipeline by Accuitis Pharmaceuticals Inc, H1 2020
Rosacea - Pipeline by Afecta Pharmaceuticals Inc, H1 2020
Rosacea - Pipeline by Aiviva BioPharma Inc, H1 2020
Rosacea - Pipeline by AlfaSigma SpA, H1 2020
Rosacea - Pipeline by AOBiome LLC, H1 2020
Rosacea - Pipeline by Biomimetix JV LLC, H1 2020
Rosacea - Pipeline by BioPharmX Inc, H1 2020
Rosacea - Pipeline by Botanix Pharmaceuticals Ltd, H1 2020
Rosacea - Pipeline by Cellix Bio Pvt Ltd, H1 2020
Rosacea - Pipeline by Cutanea Life Sciences Inc, H1 2020
Rosacea - Pipeline by Dermata Therapeutics LLC, H1 2020
Rosacea - Pipeline by ELORAC Inc, H1 2020
Rosacea - Pipeline by Emeriti Pharma AB, H1 2020
Rosacea - Pipeline by GlycoMira Therapeutics Inc, H1 2020
Rosacea - Pipeline by Hovione FarmaCiencia SA, H1 2020
Rosacea - Pipeline by Maruho Co Ltd, H1 2020
Rosacea - Pipeline by Matrisys Bioscience Inc, H1 2020
Rosacea - Pipeline by Menlo Therapeutics Inc, H1 2020
Rosacea - Pipeline by Sol-Gel Technologies Ltd, H1 2020
Rosacea - Pipeline by Sunny Pharmtech Inc, H1 2020
Rosacea - Pipeline by Tarsus Pharmaceuticals Inc, H1 2020
Rosacea - Pipeline by TWi Biotechnology Inc, H1 2020
Rosacea - Dormant Projects, H1 2020
Rosacea - Dormant Projects, H1 2020 (Contd..1), H1 2020
Rosacea - Discontinued Products, H1 2020
Number of Products under Development for Rosacea, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Rosacea - Pipeline by Accuitis Pharmaceuticals Inc, H1 2020
Rosacea - Pipeline by Afecta Pharmaceuticals Inc, H1 2020
Rosacea - Pipeline by Aiviva BioPharma Inc, H1 2020
Rosacea - Pipeline by AlfaSigma SpA, H1 2020
Rosacea - Pipeline by AOBiome LLC, H1 2020
Rosacea - Pipeline by Biomimetix JV LLC, H1 2020
Rosacea - Pipeline by BioPharmX Inc, H1 2020
Rosacea - Pipeline by Botanix Pharmaceuticals Ltd, H1 2020
Rosacea - Pipeline by Cellix Bio Pvt Ltd, H1 2020
Rosacea - Pipeline by Cutanea Life Sciences Inc, H1 2020
Rosacea - Pipeline by Dermata Therapeutics LLC, H1 2020
Rosacea - Pipeline by ELORAC Inc, H1 2020
Rosacea - Pipeline by Emeriti Pharma AB, H1 2020
Rosacea - Pipeline by GlycoMira Therapeutics Inc, H1 2020
Rosacea - Pipeline by Hovione FarmaCiencia SA, H1 2020
Rosacea - Pipeline by Maruho Co Ltd, H1 2020
Rosacea - Pipeline by Matrisys Bioscience Inc, H1 2020
Rosacea - Pipeline by Menlo Therapeutics Inc, H1 2020
Rosacea - Pipeline by Sol-Gel Technologies Ltd, H1 2020
Rosacea - Pipeline by Sunny Pharmtech Inc, H1 2020
Rosacea - Pipeline by Tarsus Pharmaceuticals Inc, H1 2020
Rosacea - Pipeline by TWi Biotechnology Inc, H1 2020
Rosacea - Dormant Projects, H1 2020
Rosacea - Dormant Projects, H1 2020 (Contd..1), H1 2020
Rosacea - Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development for Rosacea, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Accuitis Pharmaceuticals Inc
Afecta Pharmaceuticals Inc
Aiviva BioPharma Inc
AlfaSigma SpA
AOBiome LLC
Biomimetix JV LLC
BioPharmX Inc
Botanix Pharmaceuticals Ltd
Cellix Bio Pvt Ltd
Cutanea Life Sciences Inc
Dermata Therapeutics LLC
ELORAC Inc
Emeriti Pharma AB
GlycoMira Therapeutics Inc
Hovione FarmaCiencia SA
Maruho Co Ltd
Matrisys Bioscience Inc
Menlo Therapeutics Inc
Sol-Gel Technologies Ltd
Sunny Pharmtech Inc
Tarsus Pharmaceuticals Inc
TWi Biotechnology Inc
Number of Products under Development for Rosacea, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Accuitis Pharmaceuticals Inc
Afecta Pharmaceuticals Inc
Aiviva BioPharma Inc
AlfaSigma SpA
AOBiome LLC
Biomimetix JV LLC
BioPharmX Inc
Botanix Pharmaceuticals Ltd
Cellix Bio Pvt Ltd
Cutanea Life Sciences Inc
Dermata Therapeutics LLC
ELORAC Inc
Emeriti Pharma AB
GlycoMira Therapeutics Inc
Hovione FarmaCiencia SA
Maruho Co Ltd
Matrisys Bioscience Inc
Menlo Therapeutics Inc
Sol-Gel Technologies Ltd
Sunny Pharmtech Inc
Tarsus Pharmaceuticals Inc
TWi Biotechnology Inc
